BACKGROUND: The use of proton pump inhibitors for the treatment of functional dyspepsia is controversial and the role of Helicobacter pylori infection in functional dyspepsia is uncertain. AIM: To evaluate the efficacy of different doses of lansoprazole for the treatment of functional dyspepsia in Chinese patients. METHOD:Patients with a clinical diagnosis of functional dyspepsia according to the Rome II criteria and normal upper gastrointestinal endoscopy were recruited and randomised to receive: (1) lansoprazole 30 mg, (2) lansoprazole 15 mg, or (3) placebo, all given daily for four weeks. Dyspepsia symptomscores and quality of life (SF-36 score) were evaluated before and four weeks after treatment. RESULTS: A total of 453 patients were randomised. There was no difference in the proportion of patients with complete symptom relief in the lansoprazole 30 mg (23%) and lansoprazole 15 mg (23%) groups compared with the placebo group (30%). The proportion of H pylori positive patients with a complete response was similar with lansoprazole 30 mg (34%) and lansoprazole 15 mg (20%) versus placebo (22%). All symptom subgroups (ulcer-like, dysmotility-like, reflux-like, and unspecified dyspepsia) had similar proportions of patients with complete symptom relief after treatment. CONCLUSION: Proton pump inhibitor treatment is not superior to placebo for the management of functional dyspepsia in Chinese patients.
RCT Entities:
BACKGROUND: The use of proton pump inhibitors for the treatment of functional dyspepsia is controversial and the role of Helicobacter pyloriinfection in functional dyspepsia is uncertain. AIM: To evaluate the efficacy of different doses of lansoprazole for the treatment of functional dyspepsia in Chinese patients. METHOD:Patients with a clinical diagnosis of functional dyspepsia according to the Rome II criteria and normal upper gastrointestinal endoscopy were recruited and randomised to receive: (1) lansoprazole 30 mg, (2) lansoprazole 15 mg, or (3) placebo, all given daily for four weeks. Dyspepsia symptom scores and quality of life (SF-36 score) were evaluated before and four weeks after treatment. RESULTS: A total of 453 patients were randomised. There was no difference in the proportion of patients with complete symptom relief in the lansoprazole 30 mg (23%) and lansoprazole 15 mg (23%) groups compared with the placebo group (30%). The proportion of H pylori positive patients with a complete response was similar with lansoprazole 30 mg (34%) and lansoprazole 15 mg (20%) versus placebo (22%). All symptom subgroups (ulcer-like, dysmotility-like, reflux-like, and unspecifieddyspepsia) had similar proportions of patients with complete symptom relief after treatment. CONCLUSION:Proton pump inhibitor treatment is not superior to placebo for the management of functional dyspepsia in Chinese patients.
Authors: Wayne H C Hu; Kwok-fai Lam; Yeuk Hing Wong; Cindy L K Lam; Wai Mo HUIi; Kam-chuen Lai; Benjamin C Y Wong; Shiu-kum Lam Journal: J Gastroenterol Hepatol Date: 2002-05 Impact factor: 4.029
Authors: B C Delaney; M A Innes; J Deeks; S Wilson; M K Cooner; P Moayyedi; R Oakes; F D Hobbs; D Forman Journal: Cochrane Database Syst Rev Date: 2001
Authors: B C Wong; W M Wong; W H Wang; V S Tang; J Young; K C Lai; S T Yuen; S Y Leung; W H Hu; C K Chan; W M Hui; S K Lam Journal: Aliment Pharmacol Ther Date: 2001-04 Impact factor: 8.171
Authors: Paul Moayyedi; Brian E Lacy; Christopher N Andrews; Robert A Enns; Colin W Howden; Nimish Vakil Journal: Am J Gastroenterol Date: 2017-06-20 Impact factor: 10.864
Authors: B E Lacy; N J Talley; G R Locke; E P Bouras; J K DiBaise; H B El-Serag; B P Abraham; C W Howden; P Moayyedi; C Prather Journal: Aliment Pharmacol Ther Date: 2012-05-16 Impact factor: 8.171
Authors: Wayne H C Hu; S K Lam; Cindy L K Lam; W M Wong; K F Lam; K C Lai; Y H Wong; Benjamin C Y Wong; Annie O O Chan; C K Chan; Gabriel M Leung; W M Hui Journal: World J Gastroenterol Date: 2006-08-21 Impact factor: 5.742
Authors: Victoria P Y Tan; Tin K Cheung; Wai M Wong; Roberta Pang; Benjamin C Y Wong Journal: World J Gastroenterol Date: 2012-11-14 Impact factor: 5.742